

CONFERENCE 2007

THE CHILDREN'S TUMOR FOUNDATION

NF Conference Agenda - 2007

Sunday - June 10, 2007

5:00-6:45PM

Reception & Welcome Dinner

*The Forum**

Session I: Intracellular Signaling

Kokopelli - Parlor I & II

Chair: Karen Cichowski, Harvard Medical School / Brigham & Women's Hospital

6:45PM

Welcome and Foundation Updates

Kim Hunter-Schaedle, Chief Scientific Officer, The Children's Tumor Foundation

7:00-7:05PM

Introduction

Karen Cichowski, Harvard Medical School/Brigham & Women's Hospital

Keynote address:

7:05-7:35PM

Compartmentalization of Ras Signaling

Mark Philips, New York University

Session talks:

7:35-8:00PM

Merlin function in membrane organization in receptor tyrosine kinase signaling

Andrea McClatchey, Harvard Medical School/Massachusetts General Hospital

8:00-8:25PM

Phosphorylation and activity of the tumor suppressor Merlin and ERM protein Moesin are coordinately regulated by the Slik kinase.

Sarah Hughes, University of Alberta

8:25-8:50PM

Tumorigenic transformation by CPI-17 through inhibition of a merlin/ERM phosphatase

Helen Morrison, Leibniz Institute of Aging Research

8:50PM - 9:05PM

BREAK

9:05-9:30PM

Defining optic glioma pathogenesis in mice to identify new treatment strategies for children with NF1

David Gutmann, Washington University School of Medicine

9:30-9:45PM

Flow Cytometry Analysis to interrogate signaling in primary stem/progenitor cells with hyperactive Ras

Ernesto Diaz-Flores, University of California, San Francisco

9:45PM - 10:00PM

DISCUSSION

10pm

Wine Tasting

Kokopelli - Parlor III

Monday - June 11, 2007

7:30AM

Breakfast

Kokopelli - Parlor III

Session II: Cellular Mechanisms of Tumorigenesis and Tumor Suppression

Chair: Andrea McClatchey, Harvard Medical School/Massachusetts General Hospital

8:30-8:35AM

Introduction

Andrea McClatchey, Harvard Medical School/Massachusetts General Hospital

Keynote address:

8:35-9:05AM

Oncogene-induced senescence: in-vitro tool or in-vivo reality?

Daniel Peeper, Netherlands Cancer Institute

Session talks:

9:05-9:30AM

Regulated inactivation of the NF1 tumor suppressor in gliomagenesis

Karen Cichowski, Harvard Medical School/Brigham & Women's Hospital

9:30-9:55AM

Stabilization of the RasGAP by kelch proteins

Toshiaki Harashima, National Institute for Basic Science, Japan

9:55-10:20AM

Merlin - novel functions at the cell membrane?

Joseph Kissil, Wistar Institute

10:20-10:40AM

BREAK

Session III: Stem Cells

Chair: Jonathan Epstein, University of Pennsylvania

10:40-10:45AM

Introduction

Jonathan Epstein, University of Pennsylvania

Keynote address:

10:45-11:15AM

The loss of Nf1 promotes self-renewal but not tumorigenesis by neural crest stem cells
Sean Morrison, University of Michigan Center for Stem Cell Biology and Life Sciences Institute

Session talks:

11:15-11:40AM

Development of model systems for studying dermal neurofibromas
Luis Parada, University of Texas, Southwestern

11:40-12:05AM

Neurofibroma formation in mice: relevance of a glial progenitor cell
Nancy Ratner, Cincinnati Children's Hospital Medical Center

12:05-12:30PM

Is MED28 (magnin) required for maintaining stemness?
Vijaya Ramesh, Harvard Medical School/Massachusetts General Hospital

12:30-12:45PM

DISCUSSION

Session IV: Genetics and Genetic Strategies

Chair: Eric Legius, University of Leuven

7:00-7:05PM

Introduction
Eric Legius, University of Leuven

Keynote address:

7:05-7:35PM

Harnessing functional genomics to discover and validate cancer targets and pathway
William Hahn, Dana Farber Cancer Institute and Broad Institute of Harvard and MIT

Session Talks:

7:35-8:00PM

Title TBD
Eric Legius, University of Leuven

8:00-8:05PM

Schwannomatosis: a personal perspective
Fran Cone, Patient Advocate

8:05-8:20PM

INI1: Candidate Schwannomatosis gene
Theo Hulsebos, University of Amsterdam

8:20-8:35PM

The SMARCB1 (INI1) tumor suppressor in familial Schwannomatosis
Chelsea Boyd, Harvard Medical School/Massachusetts General Hospital

8:35-8:50PM
BREAK

8:50- 9:15PM
Non-cell-autonomous regulation of organismal growth by NF1
Andre Bernards, Harvard Medical School/Massachusetts General Hospital

9:15-9:30PM
CGH Comprehensive DNA copy number profiling of MPNSTs
Kiran Mantripragada, Cardiff University, Wales, UK

9:30-9:45PM
Aberrant HGF and MET expression may contribute to multiple pathological conditions in NF1
Larry Sherman, Oregon National Primate Research Center

9:45-10:00PM
Dissecting the barcode of NF1 tumor susceptibility and variable expressivity
Karlyne Reilly, NIH-NCI

10:00-10:15PM
DISCUSSION

Tuesday - June 12, 2007

7:30AM
Breakfast

Kokopelli - Parlor III

Session V: Disease Pathogenesis, Animal Models, and Development

Chairs: Luis Parada, University of Texas, Southwestern
Andre Bernards, Harvard Medical School/Massachusetts General Hospital

8:30-8:35AM
Introduction
Luis Parada, University of Texas, Southwestern

Session Talks:

8:35-8:55AM
Identification of a susceptible cell type and cellular events for NF1 neurofibroma formation
Yuan Zhu, University of Michigan

8:55-9:10AM
Conditional deletion of *Pten* tumor suppressor gene and activation of *K-Ras* oncogene results in the development of Neurofibromatoses
Caroline Gregorian, University of California, Los Angeles

9:10-9:35AM
NF1 and the cardiovascular system
Jonathan Epstein, University of Pennsylvania

9:35-9:50AM
Aberrant CNS gliogenesis in a novel zebrafish model of NF1
Jeong-Soo Lee, Dana Farber Cancer Institute

9:50-10:15AM

Breast cancer risk in women with NF1

Gareth Evans, University of Manchester

10:15-10:30AM

Role of Neurofibromin in prefrontal cortex function

Carrie Shilyansky, University of California, Los Angeles

10:30-10:35AM

BREAK

10:35-10:40AM

NF1: A Personal Perspective

Zoe Gerchick, Patient Advocate

10:40-10:55AM

Hematopoietic and mesenchymal stem/progenitor cell contributions to skeletal dysplasias in NF1

Feng-Chun Yang, Indiana University

10:55-11:10AM

ATF4 is a transcriptional target of neurofibromin signaling in osteoblasts

Florent Elefteriou, Vanderbilt University

11:10-11:25AM

NF2/Merlin Mutant Flies Are Deaf

Frances Hannan, New York Medical College

11:25-11:40PM

Role of Merlin in Neural Tube Closure, Neural Crest Cell Adhesion and Migration, and Brain Development

Elena Akhmametyeva, The Ohio State University

11:40PM-12:30PM

DISCUSSION

Federal Funding Update: Q&A

Chair: Kim Hunter-Schaedle, Children's Tumor Foundation

12:30-1:00PM

Jane Fountain, National Institute of Neurological Disorders and Stroke

Naba Bora, Neurofibromatosis Research Program (NFRP), US Army

Session VI: Therapeutic Targets, Models, and Pre-clinical Studies

Chair: Wade Clapp, Indiana University

Session Talks:

2:45-2:50PM

Introduction

Kim Hunter-Schaedle, Children's Tumor Foundation

2:50-3:15PM

The hematopoietic system is an integral component of the tumor microenvironment and is required for plexiform neurofibroma progression

Wade Clapp, University of Indiana

3:15-3:25PM

The EGFR/MPNST Connection: From Bench to Bedside

Dave Viskochil, University of Utah

3:25-3:40PM

The NF1 tumor suppressor is a critical regulator of mTOR signaling pathway

Cory Johannessen, Harvard Medical School/Brigham & Women's Hospital

3:40-3:55PM

Targeting the mTOR pathway as a potential therapeutic for MPNSTs

Gunnar Johansson, Cincinnati Children's Hospital Medical Center

3:55-4:10PM

BREAK

4:10-4:15PM

NF2: a personal perspective

Patient Advocate, TBD

4:15-4:40PM

Testing of new agents in NF2 preclinical models

Marco Giovannini, Inserm

4:40-4:55PM

Mutations that Cooperate with NF1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition 1

Jennifer O'Hara Lauchle, University of California, San Francisco

4:55-5:10PM

Pharmacological intervention with Lovastatin for learning disabilities in patients with NF1: Preliminary data in neuropsychological result in a phase 1 study

Maria Acosta, Children's National Medical Center

5:10-5:30PM

Discussion: How can we form an effective preclinical screening consortium?

ADJOURN

6:30PM - 10PM

Reception & Closing Dinner

Gondola Ride to Red Pine Lodge

**If it rains, the Welcome Reception and Dinner will be moved to the Pavilion.*